Description
Benlysta (Belimumab) is an immunosuppressive agent. It is typically used for the treatment of adults with active lupus nephritis (inflammation of the kidney that is caused by systemic lupus (an autoimmune disease which causes the body’s natural defence system (immune system) to attack healthy parts of the body)) who are receiving standard therapy. It is also used for the treatment of adults and children ≥5 years of age with active, autoantibody-positive systemic lupus erythematosus (SLE) (the most common type of lupus) who are receiving standard therapy. It may also have other uses.
Additional information
Benlysta (Belimumab)'s dosage depends on the condition, it is usually given once weekly in the usual range (200 mg - 400 mg). However, your doctor or pharmacist may have suggested a different schedule that is more appropriate for you. Your doctor or nurse will administer Benlysta (Belimumab) to you in a hospital or clinical setting. WARNING: Serious and potentially fatal (deadly) infections may occur during treatment. Use with caution and consider the risk and benefit before initiating treatment in patients with severe or chronic infections. Consider interrupting belimumab in patients who develop new infections and initiate appropriate anti-infective treatment, monitor closely. Immunosuppressant (drugs that decrease immunity) therapy may increase the risk of malignancy (cancer). May cause neurological deterioration (a decrease in brain consciousness), if it happens stop the treatment immediately. Psychiatric disorders (including depression and suicidal ideation and behavior) have been reported. Prior to and during treatment, the risk of depression and suicide should be assessed based on medical history and current psychiatric status (mental health). Advise patients and caregivers to seek medical attention for manifestations of suicidal ideation or behavior, new-onset or worsening depression, anxiety, or other mood changes, risk and benefit of continued treatment should be assessed for patients who develop such symptoms. Live vaccines should not be given within 30 days before or concurrently with belimumab. Use with caution in the elderly. These events may occur at anytime during therapy and without warning. In addition to its desired action, Benlysta (Belimumab) may cause some side effects, notably: It may cause anxiety, depression, insomnia (inability to sleep), migraine (severe headache), headache, suicidal ideation and suicidal tendencies. It may cause diarrhea, nausea, psychiatric disturbance (mental health problems), and infections. It may cause dermatological (skin) reactions, fever, and limb pain. Contraindications: Hypersensitivity (anaphylaxis: severe allergic reaction) to belimumab or any component of the formulation. Taking Benlysta (Belimumab) during pregnancy may be harmful for the baby. Women of childbearing potential should use an effective contraceptive method. Pregnant women should not use this product. If you're planning a pregnancy or become pregnant, contact your family doctor. A treatment with Benlysta (Belimumab) requires regular monitoring by a doctor. Be sure to see your doctor for all regularly scheduled appointments.Benlysta (Belimumab)
Warning
Each person may react differently to a treatment. If you think this medication may be causing side effects (including those described here, or others), talk to your doctor or pharmacist. He or she can help you to determine whether or not the medication is the source of the problem.
There are no reviews yet.
Reviews